Thibaut Roulon
Board Member @Nouscom
Signup · Get unlimited contacts
WORK HISTORY
Board Member @Nouscom
NousCom develops a portfolio of neoantigen cancer vaccines.Its lead product - Nous-209 - is an off-the-shelf vaccine for cancer interception in Lynch syndrome patients and for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) cancers. It is currently in phase II clinical trial.NousCom also develops Nous-PEV - a personnalized vaccine for cancer.
EDUCATION
Lycée Henri IV
Classes préparatoires aux grandes écoles (CPGE)
CentraleSupélec
Master (Ingenieur Degree), Engineering / Biotechnology
Pierre and Marie Curie University
Doctor of Philosophy (Ph.D.), Molecular Biophysics
SKILLS
ABOUT THIBAUT ROULON
Senior Investment Director at Bpifrance with 20 years of experience in Venture Capital.In charge of investments in Life Sciences companies (Seed, Venture, IPO, PIPE).Member of Bpifrance investment committee for small cap growth and buyout investments.Experienced board member.Previous experiences in big pharma, academic research and biotech (US).
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.